Encoberminogene rezmadenovec (XyloCor Therapeutics Inc.) is an investigational gene therapy proposed for treatment of refractory angina pectoris. The therapy is administered directly to cardiac muscle via minithoracotomy.
Encoberminogene rezmadenovec (XyloCor Therapeutics Inc.) is an investigational gene therapy proposed for treatment of refractory angina pectoris. The therapy is administered directly to cardiac muscle via minithoracotomy.